Santen Pharmaceutical Co (JP:4536) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Santen Pharmaceutical Co. reported a slight revenue increase of 0.4% for the six months ending September 2024, but faced declines in core operating profit and net profit by 5.7% and 10.3% respectively. Despite these challenges, the company plans to maintain its dividend payouts, signaling confidence in its long-term financial health.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.